Analysts Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) PT at $183.89

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given an average recommendation of “Moderate Buy” by the twenty brokerages that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $183.89.

Several research analysts have recently issued reports on the stock. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. UBS Group upped their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Royal Bank of Canada lifted their target price on Sarepta Therapeutics from $181.00 to $182.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Cantor Fitzgerald restated a “neutral” rating and issued a $152.00 price target on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Finally, Raymond James reaffirmed an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th.

Sarepta Therapeutics Stock Up 2.3 %

Shares of NASDAQ:SRPT opened at $127.08 on Friday. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The stock has a fifty day simple moving average of $129.00 and a two-hundred day simple moving average of $132.36. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25. The stock has a market capitalization of $12.01 billion, a price-to-earnings ratio of 1,155.27 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same quarter in the previous year, the firm earned ($0.27) EPS. Sarepta Therapeutics’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, research analysts anticipate that Sarepta Therapeutics will post 1.45 earnings per share for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In related news, Director Michael Andrew Chambers bought 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Michael Andrew Chambers bought 37,038 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were bought at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. Farallon Capital Management LLC grew its position in shares of Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. Principal Financial Group Inc. grew its holdings in Sarepta Therapeutics by 693.7% during the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after buying an additional 317,277 shares in the last quarter. Vanguard Group Inc. increased its stake in Sarepta Therapeutics by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after acquiring an additional 243,180 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in Sarepta Therapeutics by 2,257.8% in the 1st quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company’s stock worth $31,135,000 after acquiring an additional 230,300 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Sarepta Therapeutics by 146.3% during the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock worth $42,809,000 after acquiring an additional 160,942 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.